Acute pulmonary embolism: part II: risk stratification, treatment, and prevention.

Pulmonary embolism (PE) presents with a wide clinical spectrum, from asymptomatic small PE to life-threatening major PE that causes hypotension and cardiogenic shock (Table). Traditionally, our risk assessment is done by gestalt . However, a more precise risk assessment can be obtained by using a formal clinical scoring system, such as the Geneva Prognostic Index.1 The Geneva Prognostic Index uses an 8-point scoring system and identifies 6 predictors of adverse outcome: 2 points each for cancer and hypotension and 1 point each for heart failure, prior deep vein thrombosis (DVT), arterial hypoxemia, and ultrasound-proven DVT. As points accumulate, prognosis worsens. Remarkably, hypoxemia accounts for only 1 of 8 points. View this table: Risk Stratification Physical examination, ECG, chest radiograph, CT scan, and echocardiogram2 can provide evidence of right ventricular dysfunction, a key prognostic marker of high risk and increased major adverse clinical events. The most recent development in prognostication is the use of biomarkers2a such as troponin elevation,3 which indicates right ventricular microinfarction, and elevations of pro-B–type natriuretic peptide4 and B-type natriuretic peptide, which indicate right ventricular overload.5,6 On physical examination, general clinical appearance is useful, but young patients may appear deceptively well despite massive PE. Clues to right heart failure include distended jugular veins, an accentuated pulmonic heart sound, and a tricuspid regurgitation murmur. The ECG may show a classic S1Q3T3 pattern but more often will demonstrate a less commonly recognized sign of right ventricular strain, T wave inversion in leads V1 through V4. New incomplete or complete right bundle-branch block is a very useful sign of right ventricular dysfunction. The chest radiograph may show enlarged pulmonary arteries, especially an enlarged right descending pulmonary artery, indicating pulmonary hypertension. Although the chest CT scan is performed primarily to detect or exclude PE, information about …

[1]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[2]  S. Goldhaber,et al.  Acute Pulmonary Embolectomy: A Contemporary Approach , 2002, Circulation.

[3]  P. Romano,et al.  A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. , 2000, Archives of internal medicine.

[4]  W. Ageno,et al.  Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism , 2003, Annals of Internal Medicine.

[5]  P D Stein,et al.  Alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism. , 1995, Chest.

[6]  M. Gent,et al.  Comparison of Low-Intensity Warfarin Therapy With Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism , 2004 .

[7]  O. Linder,et al.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. , 1997, The New England journal of medicine.

[8]  K. Mcintyre,et al.  Long-term benefit of thrombolytic therapy in patients with pulmonary embolism , 2000, Vascular medicine.

[9]  Samuel Z Goldhaber,et al.  Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) , 1999, The Lancet.

[10]  J. Vandenbroucke,et al.  Oral contraceptives and the risk of venous thrombosis. , 2001, The New England journal of medicine.

[11]  U. Janssens,et al.  Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. , 1999, Circulation.

[12]  F. Rosendaal,et al.  Heritability of clotting factors and the revival of the prothrombotic state , 2002, The Lancet.

[13]  C. Francis,et al.  Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty , 2002, Annals of Internal Medicine.

[14]  S. Schulman,et al.  A Comparison of Six Weeks With Six Months of Oral Anticoagulant Therapy After a First Episode of Venous Thromboembolism , 1996 .

[15]  Kenneth E Wood,et al.  Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. , 2002, Chest.

[16]  P. Ravaud,et al.  A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. , 2000, JAMA.

[17]  B. Lämmle,et al.  Accuracy of d‐dimer/fibrinogen ratio to predict pulmonary embolism: a prospective diagnostic study , 2003, Journal of thrombosis and haemostasis : JTH.

[18]  H. Büller,et al.  Brain Natriuretic Peptide as a Predictor of Adverse Outcome in Patients With Pulmonary Embolism , 2003, Circulation.

[19]  J. Hosking,et al.  The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. , 1997, Annals of surgery.

[20]  F. Barral,et al.  A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. , 1998, The New England journal of medicine.

[21]  S. Goldhaber,et al.  Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. , 2003, Circulation.

[22]  D. Slosman,et al.  Performance of Helical Computed Tomography in Unselected Outpatients with Suspected Pulmonary Embolism , 2001, Annals of Internal Medicine.

[23]  J. Beckman,et al.  Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism , 2003, Thrombosis and Haemostasis.

[24]  I. Durieu,et al.  Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis , 2001, Circulation.

[25]  M. Gent,et al.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[26]  O. Hess,et al.  Low Pro-Brain Natriuretic Peptide Levels Predict Benign Clinical Outcome in Acute Pulmonary Embolism , 2003, Circulation.

[27]  M. Fishbein,et al.  Acute pulmonary embolism: don't ignore the platelet. , 2002, Circulation.

[28]  S. Goldhaber,et al.  Arterial blood gas analysis in the assessment of suspected acute pulmonary embolism. , 1996, Chest.

[29]  S. Rapaport,et al.  Correction of Excessive Anticoagulation with Low-Dose Oral Vitamin K1 , 1997, Annals of Internal Medicine.

[30]  R. Raschke,et al.  The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. , 1996, Archives of internal medicine.

[31]  M. Gould,et al.  Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. , 1999, Annals of internal medicine.

[32]  T. Perneger,et al.  Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention , 2002, The Lancet.

[33]  K. Schulman,et al.  Cost-effectiveness analyses. , 1995, The New England journal of medicine.

[34]  S. Schulman,et al.  Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. , 2000, The New England journal of medicine.

[35]  S. Goldhaber Integration of catheter thrombectomy into our armamentarium to treat acute pulmonary embolism. , 1998, Chest.

[36]  S. Schulman,et al.  Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.

[37]  S. Goldhaber Echocardiography in the Management of Pulmonary Embolism , 2002, Annals of Internal Medicine.

[38]  R. Goldszer,et al.  The critical pathways of an anticoagulation service. , 2003, Critical Pathways in Cardiology.

[39]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[40]  W. Haire Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. , 2003, Current hematology reports.

[41]  P. Ridker,et al.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[42]  S. Goldhaber,et al.  New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. , 2000, Chest.

[43]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[44]  M. Olschewski,et al.  Importance of Cardiac Troponins I and T in Risk Stratification of Patients With Acute Pulmonary Embolism , 2002, Circulation.

[45]  T. Perneger,et al.  Predicting Adverse Outcome in Patients with Acute Pulmonary Embolism: A Risk Score , 2000, Thrombosis and Haemostasis.

[46]  P. Cecchini,et al.  Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. , 2000, Circulation.

[47]  P. Grenier,et al.  Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study , 2002, The Lancet.

[48]  K. Mann,et al.  Oral Anticoagulation Thresholds , 2001, Circulation.

[49]  C. Kessler,et al.  Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate , 2002, Annals of Internal Medicine.

[50]  U. Seligsohn,et al.  Genetic susceptibility to venous thrombosis. , 2001, The New England journal of medicine.

[51]  R. Crapo,et al.  Single-breath carbon monoxide diffusing capacity. , 2001, Clinics in chest medicine.

[52]  E. Braunwald,et al.  Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion , 1993, The Lancet.

[53]  J. Douketis,et al.  Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials , 2001, The Lancet.

[54]  M. Prins,et al.  Single-Detector Helical Computed Tomography as the Primary Diagnostic Test in Suspected Pulmonary Embolism: A Multicenter Clinical Management Study of 510 Patients , 2003, Annals of Internal Medicine.

[55]  olfgang,et al.  HEPARIN PLUS ALTEPLASE COMPARED WITH HEPARIN ALONE IN PATIENTS WITH SUBMASSIVE PULMONARY EMBOLISM , 2002 .

[56]  S. Goldhaber,et al.  Normal D-dimer levels in emergency department patients suspected of acute pulmonary embolism. , 2002, Journal of the American College of Cardiology.

[57]  M. Prins,et al.  An association between atherosclerosis and venous thrombosis. , 2003, The New England journal of medicine.

[58]  S. Goldhaber,et al.  Prognostic Role of Brain Natriuretic Peptide in Acute Pulmonary Embolism , 2003, Circulation.

[59]  V. Kakkar,et al.  Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. , 2001, The New England journal of medicine.

[60]  S. Goldhaber,et al.  Laboratory thrombophilias and venous thromboembolism , 2002, Vascular medicine.

[61]  F Lapostolle,et al.  Severe pulmonary embolism associated with air travel. , 2001, The New England journal of medicine.

[62]  M Gent,et al.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.

[63]  S. Schulman,et al.  A randomized, controlled, dose‐guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I , 2003, Journal of thrombosis and haemostasis : JTH.

[64]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[65]  lexander,et al.  Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer , 2002 .

[66]  J. Bartholomew,et al.  Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia , 2001, Circulation.

[67]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[68]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[69]  M Gent,et al.  Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer , 2000, Thrombosis and Haemostasis.